 |
 |
|
|
|  PubMed
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 April 2003 | Volume 138 Issue 8 | Pages 639-643
Background: Although many observers believe that cancer chemotherapy is overused at the end of life, there are no published data on this.
Objective: To determine the frequency and duration of chemotherapy use in the last 6 months of life stratified by type of cancer, age, and sex.
Design: Retrospective cohort analysis.
Setting: Administrative databases from Massachusetts and California.
Patients: All Medicare patients who died of cancer in Massachusetts and 5% of Medicare cancer decedents in California in 1996.
Measurements: Use of intravenous chemotherapy agents, chemotherapy administration, or medical evaluation for chemotherapy from Medicare billing data for each patient in 30-day periods from the date of death backward.
Results: In Massachusetts, 33% of cancer decedents older than 65 years of age received chemotherapy in the last 6 months of life, 23% in the last 3 months, and 9% in the last month. In California, the percentages were 26%, 20%, and 9%, respectively. Chemotherapy use greatly declined with age. Chemotherapy use was similar for patients with breast, colon, and ovarian cancer and those with cancer generally considered unresponsive to chemotherapy, such as pancreatic, hepatocellular, or renal-cell cancer or melanoma. Patients with types of cancer that are unresponsive to chemotherapy had shorter duration of chemotherapy use.
Conclusion: Among patients who died of cancer, chemotherapy was used frequently in the last 3 months of life. The cancer's responsiveness to chemotherapy does not seem to influence whether dying patients receive chemotherapy at the end of life.
Editors' Notes
Context
Contribution
Implications
–The Editors
Author and Article Information
From Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland; Boston University School of Medicine, and Harvard Vanguard Associates, Boston, Massachusetts; and National Bureau of Economic Research, Palo Alto, California.
Disclaimer: The opinions expressed are those of the authors and do not necessarily reflect the opinions or policies of the National Institutes of Health or the U.S. Department of Health and Human Services.
Acknowledgments: The authors thank Joan Warren, Deborah Schrag, and Peter Bach for helpful advice and comments on the project and manuscript. They also thank many questioners at the 2001 Annual American Society of Clinical Oncology meeting for helpful challenges.
Grant Support: This study was conducted under a contract from the Department of Clinical Bioethics, Clinical Center, National Institutes of Health to the Boston University School of Medicine and by a grant from the National Institutes of Aging.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Ezekiel J. Emanuel, MD, PhD, Department of Clinical Bioethics, Warren G. Magnuson Clinical Center, National Institutes of Health, Building 10, Room 1C118, Bethesda, MD 20892-1156.
Current Author Addresses: Dr. Emanuel: Department of Clinical Bioethics, Warren G. Magnuson Clinical Center, National Institutes of Health, Building 10, Room 1C118, Bethesda, MD 20892-1156.
Mr. Young-Xu: Harvard University, School of Public Health, 677 Huntington Avenue, Boston, MA 02115.
Dr. Levinsky: Boston University Medical Center, 715 Albany Street, Boston, MA 02118.
Dr. Gazelle: Harvard Vanguard Medical Association, 133 Brookline Avenue, Boston, MA 02215.
Ms. Saynina: National Bureau of Economic Research, 30 Alta Road, Stanford, CA 94305.
Dr. Ash: Boston University School of Medicine, 720 Harrison Avenue, #1108, Boston, MA 02118.
Author Contributions: Conception and design: E.J. Emanuel, G. Gazelle, A.S. Ash.
Analysis and interpretation of data: E.J. Emanuel, Y. Young-Xu, N.G. Levinsky, G. Gazelle, O. Saynina, A.S. Ash.
Drafting of the article: E.J. Emanuel, Y. Young-Xu, N.G. Levinsky, G. Gazelle, A.S. Ash.
Critical revision of the article for important intellectual content: E.J. Emanuel, Y. Young-Xu, N.G. Levinsky, G. Gazelle, A.S. Ash.
Final approval of the article: E.J. Emanuel, Y. Young-Xu, N.G. Levinsky, G. Gazelle, A.S. Ash.
Statistical expertise: A.S. Ash.
Obtaining of funding: E.J. Emanuel.
Collection and assembly of data: Y. Young-Xu. BRIEF COMMUNICATION
Chemotherapy Use among Medicare Beneficiaries at the End of Life
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  S. Kao, J. Shafiq, J. Vardy, and D. Adams Use of chemotherapy at end of life in oncology patients Ann. Onc., May 25, 2009; (2009) mdp027v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Wilson Cancer Care: A Microcosm of the Problems Facing All of Health Care Ann Intern Med, April 21, 2009; 150(8): 573 - 576. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hanchate, A. C. Kronman, Y. Young-Xu, A. S. Ash, and E. Emanuel Racial and Ethnic Differences in End-of-Life Costs: Why Do Minorities Cost More Than Whites? Arch Intern Med, March 9, 2009; 169(5): 493 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Tang, S.-C. Wu, Y.-N. Hung, E.-W. Huang, J.-S. Chen, and T.-W. Liu Trends in quality of end-of-life care for Taiwanese cancer patients who died in 2000-2006 Ann. Onc., February 1, 2009; 20(2): 343 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Setoguchi, C. C. Earle, R. Glynn, M. Stedman, J. M. Polinski, C. P. Corcoran, and J. S. Haas Comparison of Prospective and Retrospective Indicators of the Quality of End-of-Life Cancer Care J. Clin. Oncol., December 10, 2008; 26(35): 5671 - 5678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Mack, S. Joffe, J. M. Hilden, J. Watterson, C. Moore, J. C. Weeks, and J. Wolfe Parents' Views of Cancer-Directed Therapy for Children With No Realistic Chance for Cure J. Clin. Oncol., October 10, 2008; 26(29): 4759 - 4764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C von Plessen, T-E Strand, T Wentzel-Larsen, E Omenaas, N Wilking, S Sundstrom, and S Sorenson Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway: a national study Thorax, October 1, 2008; 63(10): 866 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Van den Block, R. Deschepper, N. Bossuyt, K. Drieskens, S. Bauwens, V. Van Casteren, and L. Deliens Care for Patients in the Last Months of Life: The Belgian Sentinel Network Monitoring End-of-Life Care Study Arch Intern Med, September 8, 2008; 168(16): 1747 - 1754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. McFarlane, J. Riggins, and T. J. Smith SPIKE$: A Six-Step Protocol for Delivering Bad News About the Cost of Medical Care J. Clin. Oncol., September 1, 2008; 26(25): 4200 - 4204. [Full Text] [PDF]
|
|
|
|
 |
|
 A B Astrow, J R Sood, M T Nolan, P B Terry, L Clawson, J Kub, M Hughes, and D P Sulmasy Decision-making in patients with advanced cancer compared with amyotrophic lateral sclerosis J. Med. Ethics, September 1, 2008; 34(9): 664 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Earle, M. B. Landrum, J. M. Souza, B. A. Neville, J. C. Weeks, and J. Z. Ayanian Aggressiveness of Cancer Care Near the End of Life: Is It a Quality-of-Care Issue? J. Clin. Oncol., August 10, 2008; 26(23): 3860 - 3866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Keam, D.-Y. Oh, S.-H. Lee, D.-W. Kim, M. R. Kim, S.-A. Im, T.-Y. Kim, Y.-J. Bang, and D. S. Heo Aggressiveness of Cancer-Care near the End-of-Life in Korea Jpn. J. Clin. Oncol., May 1, 2008; 38(5): 381 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Talcott Prostate Cancer Quality of Life: Beyond Initial Treatment and the Patient J. Clin. Oncol., September 20, 2007; 25(27): 4155 - 4156. [Full Text] [PDF]
|
|
|
|
 |
|
 V. H. Menec, L. Lix, S. Nowicki, and O. Ekuma Health Care Use at the End of Life Among Older Adults: Does It Vary by Age? J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2007; 62(4): 400 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Bach Costs of Cancer Care: A View From the Centers for Medicare & Medicaid Services J. Clin. Oncol., January 10, 2007; 25(2): 187 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Matsuyama, S. Reddy, and T. J. Smith Why Do Patients Choose Chemotherapy Near the End of Life? A Review of the Perspective of Those Facing Death From Cancer J. Clin. Oncol., July 20, 2006; 24(21): 3490 - 3496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Earle and J. Z. Ayanian Looking Back From Death: The Value of Retrospective Studies of End-of-Life Care J. Clin. Oncol., February 20, 2006; 24(6): 838 - 840. [Full Text] [PDF]
|
|
|
|
|
|
T. Bodenheimer and A. Fernandez High and Rising Health Care Costs. Part 4: Can Costs Be Controlled While Preserving Quality? Ann Intern Med, July 5, 2005; 143(1): 26 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Back, R. M. Arnold, W. F. Baile, J. A. Tulsky, and K. Fryer-Edwards Approaching Difficult Communication Tasks in Oncology CA Cancer J Clin, May 1, 2005; 55(3): 164 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Bach, D. Schrag, and C. B. Begg Resurrecting Treatment Histories of Dead Patients: A Study Design That Should Be Laid to Rest JAMA, December 8, 2004; 292(22): 2765 - 2770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Shanafelt, C. Loprinzi, R. Marks, P. Novotny, and J. Sloan Are Chemotherapy Response Rates Related to Treatment-Induced Survival Prolongations in Patients With Advanced Cancer? J. Clin. Oncol., May 15, 2004; 22(10): 1966 - 1974. [Abstract] [Full Text] [PDF]
|
|
